Skip to content
MarketScale
‹ Back to IndustriesSciences

To Create a Private Market Do Governments Need To Kickstart Space Programs?

Bhavya Lal, Associate Administrator for Technology, Policy, and Strategy at NASA, joined Hosts Charity Weeden and Chris Blackerby to discuss the transition to her role at NASA. As a former employee at the Institute for Defense Analysis and the Science and Technology Institute, Lal switched from research to management. “I’m really blessed with the leadership…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · And Diversity.And Strategy at NasaAssociate Administrator for TechnologyBhavya Lal
Share

Key takeaways

01

Bhavya Lal, Associate Administrator for Technology, Policy, and Strategy at NASA, joined Hosts Charity Weeden and Chris Blackerby to discuss the transition to her role at NASA.

02

As a former employee at the Institute for Defense Analysis and the Science and Technology Institute, Lal switched from research to management.

03

“I’m really blessed with the leadership…

Bhavya Lal, Associate Administrator for Technology, Policy, and Strategy at NASA, joined Hosts Charity Weeden and Chris Blackerby to discuss the transition to her role at NASA.

As a former employee at the Institute for Defense Analysis and the Science and Technology Institute, Lal switched from research to management. “I’m really blessed with the leadership at NASA,” she said of her role.

Lal grew up in a STEM family; her father was an electrical engineer and her mother studied math. “The idea that one could be gifted was never even brought up. You did well in school because you worked hard, not because you were smart or had some advantage,” Lal said of her upbringing. “I’ve found the idea that hard work can overcome any disadvantages to be my superpower.”

Daily, Lal has 10 to 15 meetings, which makes for long hours. She works closely with the National Space Council, the Office of Science and Technology Policy, and the Federal Aviation Administration. She has found some of the hardest things in society are not technical but are policy-based and must be examined wholistically with a long-term view.

Governments and individuals or businesses are the space industry customers. However, not many individuals and businesses cannot afford services, so Lal believes the government should kickstart certain programs and then private customers will emerge. “Let’s not have this mad dash to discovering a private market that may not already exist. Let’s work to build it,” she said.

In terms of diversity, Lal emphasized the importance of the fields individuals come from. “There’s a myriad of examples of how disruptive thinking comes from the outside,” she stated. “Our innovations will come from diverse thoughts, not trying to repeat what we’ve done before.”

More in This Series

About the author

CB
Chris Blackerby

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

  • 01Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.
  • 02The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.
  • 03Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Jul 31, 2026

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512